Ultragenyx Pharmaceutical Inc. (RARE) Form 10-Q — Aug 4, 2026
Ultragenyx posted Q2 2026 total revenues of $214 million, up 28% year over year, on Crysvita product sales of $54 million, Crysvita royalties of $102 million, and 50% growth for Evkeeza, while the quarterly net loss narrowed to $92 million ($0.90 per share) from $115 million a year earlier. Liquidity fell to $436 million in cash, cash equivalents, and marketable securities from $737 million at December 31, 2025 after $294 million of first-half operating cash burn.
Key figures
- Revenue
- 214
- Guidance
- Existing capital sufficient for at least the next 12 months; R&D expenses expected to decrease in the near term; management expects profitability in 2027
- Revenue Yoy
- 28%
- Total Assets
- 1264
- Cash Position
- 436
- Shares Outstanding
- 98588873
- Ux111 pdufa date
- 2026-09-19
- Atm capacity musd
- 350
- Dtx401 pdufa date
- 2026-08-23
- Kkc receivable musd
- 94
- Q2 product sales musd
- 112
- Six month revenue musd
- 350
- Cash and equivalents musd
- 125
- Gtx102 aspire data timing
- September or October 2026
- Catalent counterclaim musd
- 8
- Liquidity dec 31 2025 musd
- 737
- Q2 revenue prior year musd
- 167
- Catalent damages sought musd
- 100
- Atm net proceeds to date musd
- 80
- Q2 crysvita royalty revenue musd
- 102
- Q2 product sales prior year musd
- 81
- Dojolvi orphan exclusivity expiry
- 2027-06-30
- Restructuring workforce reduction
- approximately 10%
- Restructuring charges six months rd musd
- 28
- Liabilities for future royalty sales musd
- 1202
- Omers royalty sale net proceeds nov 2025 musd
- 392
Price after filing
1 day: -3.9%7 days: +3.5%30 days: +1.9%
Close on the filing date to close N calendar days later (from $26.04). Historical, not a forecast.
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.